NL-OMON44313招募中不适用
Development of novel clinical endpoints for interventional clinical trials with a regulatory and patient access intention in patients with intermediate age-related macular degeneration (AMD) - MACUSTAR - MACUSTAR
niversity Hospital Bonn, UKB0 个研究点目标入组 80 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •General Inclusion criteria (applicable to all groups)
- •1. Male and female subjects.
- •2. Aged 55 - 85 years at baseline.
- •3. Able and willing to provide written informed consent and to comply with the study protocol visits and assessments.;Intermediate AMD
- •1. Study eye must have iAMD and,
- •2. The fellow eye must have iAMD and/or, in addition, extrafoveal GA (no atrophy within the central ETDRS subfield), maximum total GA size is 1.25 mm2.
- •Definition of iAMD: large drusen >125 µm and/or any AMD pigmentary abnormalities, that are definite hyper- or hypopigmentary abnormalities associated with medium or large drusen but not associated with other known disease entities. (See table 4-1 for more specifications). If both eyes are eligible for the study based on inclusion criteria, the eye with better visual acuity (i.e. on BCVA) will be selected as the study eye as this will improve reliability of functional testing and quality of image acquisition and thus improve sensitivity to detect change over time. In cases in which both eyes have the same visual acuity, the study eye will be selected at random by the investigator.
- •3. ETDRS letter chart BCVA in the study eye not worse than 72 letters (approximately 20/40 Snellen VA equivalent).
- •4. All general inclusion criteria.;Late AMD
- •1. Subjects with bilateral GA, bilateral nAMD or nAMD in one eye and GA in the other (See table 4-1 for more specifications).
- •2. BCVA between 20/80 and 20/200 in study eye.
- •3. All general inclusion criteria.;Early AMD
- •1. Subjects with medium drusen > 63µm and <= 125µm and no AMD pigmentary abnormalities in both eyes and not signs of intermediate or late AMD. (See table 4-1 for more specifications).
- •2. All general inclusion criteria. ;No AMD
- •1. No signs of early, intermediate or late AMD in both eyes. (See table 4-1 for more specifications).
- •2. All general inclusion criteria only.
排除标准
- •General Exclusion criteria (applicable to all groups)
- •1. Media opacity or eye movement disorder (nystagmus) that interferes with retinal imaging data quality in the opinion of the investigator.
- •2. Severe ptosis, extraocular motility restriction or head tremor preventing adequate fundus visualization in the opinion of the investigator.
- •3. Any signs of nAMD or GA according to the criteria descried in table 4-1 (does not apply to the late AMD group).
- •4. Any concurrent intraocular condition in the study eye (e. g. glaucoma or cataract) that, in the opinion of the investigator would either require surgical intervention during the study to prevent or treat visual loss that might result from that condition or affect interpretation of study results.
- •5. Severe non-proliferative diabetic retinopathy, or proliferative diabetic retinopathy.
- •6. Any diabetic macular edema or macular disease
- •7. Ocular disorders in the study eye (i. e., pre-retinal membrane) at the time of enrolment that may confound interpretation of study results and compromise visual acuity.
- •8. Diagnosis of uncontrolled glaucoma with intraocular pressure of >30 mmHg (despite current pharmacological or non-pharmacological treatment).
- •9. Known systemic illness which in the opinion of the investigator will prevent from actively participating in the study.
- •10. Concomitant treatment for AMD in either eye (concomitant use of vitamins/supplements is not excluded; does not apply to the late AMD group).
- •11. Any periocular or intravitreal injections (IVT) in either eye (does not apply to the late AMD group).
- •12. Participation in any other interventional trial.
- •13. Obvious retinal changes due to causes other than AMD (e.g. evidenced by an existing diagnosis of monogenetic macular dystrophies, Stargardt disease, cone rod dystrophy, or toxic maculopathies).
- •14. Any history of allergies to fluorescein.;Intermediate AMD
- •1. Any GA in the study eye
- •2. Any extrafoveal GA larger than 1.25 mm2 (as defined above) in the fellow eye.
- •3. All general exclusion criteria.;Late AMD
- •1. All general exclusion criteria only.;Early AMD
- •1. Intermediate or late AMD (following Beckman classification) in any eye.
- •2. All general exclusion criteria.;No AMD
- •1. Early to late AMD (following Beckman classification) in any eye.
- •2. All general exclusion criteria.
研究者
相似试验
进行中（未招募）
不适用
Development of Novel Clinical Endpoints in Intermediate AMDAge Related Macular Degeneration (AMD)NCT03349801Frank G. Holz718
进行中（未招募）
Unknown
Investigating the effects of intravenous fluids and imatinib in human volunteers with a sepsis-like stateInfections and InfestationsSepsisISRCTN16409847Belfast Health and Social Care Trust65
进行中（未招募）
不适用
Investigation of clinical endpoints for treatment-induced gastroesophageal reflux disease (GERD) symptom changes - COMPETITIOgastroesophageal reflux diseaseMedDRA version: 8.1Level: LLTClassification code 10017885Term: Gastrooesophageal reflux diseaseEUCTR2006-000926-30-DEALTANA Pharma AG660
进行中（未招募）
不适用
Investigation of clinical endpoints for treatment-induced gastroesophageal reflux disease (GERD) symptom changes - COMPETITIOgastroesophageal reflux diseaseMedDRA version: 8.1Level: lltClassification code 10017885EUCTR2006-000926-30-HUALTANA Pharma AG660
进行中（未招募）
不适用
Investigation of clinical endpoints for treatment-induced gastroesophageal reflux disease (GERD) symptom changes - COMPETITIOEUCTR2006-000926-30-ATALTANA Pharma AG660